| Trial ID: | L4955 |
| Source ID: | NCT01720303
|
| Associated Drug: |
Repaglinide
|
| Title: |
Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: repaglinide|DRUG: isophane human insulin|DRUG: insulin
|
| Outcome Measures: |
Primary: Change in HbA1c | Secondary: Change in FBG (Fasting Blood Glucose)|Change in body weight
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
159
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2002-09-19
|
| Completion Date: |
2003-04-10
|
| Results First Posted: |
|
| Last Update Posted: |
2017-02-20
|
| Locations: |
Novo Nordisk Investigational Site, Beijing, Beijing, 100101, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, 200040, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, 200433, China
|
| URL: |
https://clinicaltrials.gov/show/NCT01720303
|
